USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
MYOMICS, INC.
Address:
MYOMICS, INC.
148 West River Street
PROVIDENCE, RI 02904 2615
Phone:
N/A
URL:
N/A
EIN:
134266372
DUNS:
139717537
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $298,039.00 3
SBIR Phase II $1,491,944.00 2
STTR Phase I $99,939.00 1

Award List:

SBIR Phase I: Physiologic High Throughput Screening of Bioengineered Tissues

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$99,991.00
Agency:
NSF
Principal Investigator:
Abstract:
The Small Business Innovation Research (SBIR) Phase I project will develop an innovative high-throughput/ high content drug screening platform utilizing three-dimensional human skeletal muscle tissue constructs which mimic in vivo skeletal muscle to quantify muscle force generation. The proposed… More

Electro-Mechanical Micro-Post Array to Detect In Vitro Muscle Contraction

Award Year / Program / Phase:
2006 / STTR / Phase I
Award Amount:
$99,939.00
Agency:
HHS
Principal Investigator:
Research Institution:
MIRIAM HOSPITAL
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Myomics? technology to be developed in this Phase 1 project is based upon an in vitro skeletal muscle tissue force measurement technique for high throughput screening (HTS) of compounds to attenuate muscle weakness. The technology, termed Patterned… More

High Content Screening for Muscular Dystrophy

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$99,912.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Myomics' drug screening technology to be developed in this Phase 1 SBIR project for Duchene muscular dystrophy (DMD) is based upon an in vitro skeletal muscle tissue force measurement technique for high content screenin g (HCS) of compounds to attenuate muscle… More

SBIR Phase II: Physiologic High Throughput Screening of Bioengineered Tissues

Award Year / Program / Phase:
2007 / SBIR / Phase II
Award Amount:
$499,956.00
Agency:
NSF
Principal Investigator:
Abstract:
This Small Business Innovation Research (SBIR) Phase II research develops an innovative high-throughput/high content drug screening platform that utilizes three-dimensional human skeletal muscle tissue constructs that mimic in vivo skeletal muscle to quantify muscle force generation. Significant… More

High Content Drug Screening with Cardiac Tissue

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$98,136.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Myomics, Inc. has developed High Content Drug Screening (HCS) technology for in vitro testing of compounds which alter contractile forces generated by miniaturized tissue engineered organs (Myo-Force Assay SystemTM, MFA STM). Myomics' 3-D tissue/force sensor… More

High Content Screening for Muscular Dystrophy

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$991,988.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Duchenne Muscular Dystrophic (DMD) is a fatal genetic disease affecting tens of thousands of boys in the U.S. There is currently no cure for the disease and few drugs are available to slow the progressive loss in skele tal muscle strength. Glucocorticoids such… More